Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – Research Report).
BeiGene (BGNE)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on BeiGene on November 26 and set a price target of $234.00. The company’s shares closed last Wednesday at $206.16.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $250.46 average price target, which is a 24.4% upside from current levels. In a report issued on November 12, Leerink Partners also maintained a Buy rating on the stock with a $290.00 price target.
See the top stocks recommended by analysts >>
Teladoc (TDOC)
J.P. Morgan analyst Lisa Gill maintained a Hold rating on Teladoc on November 26 and set a price target of $13.00. The company’s shares closed last Wednesday at $11.43.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $11.16, implying a -3.9% downside from current levels. In a report issued on November 21, Deutsche Bank also maintained a Hold rating on the stock with a $12.00 price target.
Read More on BGNE:
